Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Biomarkers of Exposure among U.S. Adult Cigar Smokers: Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014).

Chang CM, Rostron BL, Chang JT, Corey CG, Kimmel HL, Sosnoff CS, Goniewicz ML, Edwards KC, Hatsukami DK, Wang Y, Del Valle-Pinero AY, Yang M, Travers MJ, Arnstein S, Taylor K, Conway K, Ambrose BK, Borek N, Hyland A, Wang L, Blount BC, van Bemmel DM.

Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):943-953. doi: 10.1158/1055-9965.EPI-18-0539. Epub 2019 Feb 7.

PMID:
30733305
2.

Comparison of Nicotine and Toxicant Exposure in Users of Electronic Cigarettes and Combustible Cigarettes.

Goniewicz ML, Smith DM, Edwards KC, Blount BC, Caldwell KL, Feng J, Wang L, Christensen C, Ambrose B, Borek N, van Bemmel D, Konkel K, Erives G, Stanton CA, Lambert E, Kimmel HL, Hatsukami D, Hecht SS, Niaura RS, Travers M, Lawrence C, Hyland AJ.

JAMA Netw Open. 2018 Dec 7;1(8):e185937. doi: 10.1001/jamanetworkopen.2018.5937.

3.

Patterns and correlates of polysubstance use among US youth aged 15-17 years: wave 1 of the Population Assessment of Tobacco and Health (PATH) Study.

Silveira ML, Green VR, Iannaccone R, Kimmel HL, Conway KP.

Addiction. 2019 Jan 4. doi: 10.1111/add.14547. [Epub ahead of print]

PMID:
30614093
4.

Urinary concentrations of monohydroxylated polycyclic aromatic hydrocarbons in adults from the U.S. Population Assessment of Tobacco and Health (PATH) Study Wave 1 (2013-2014).

Wang Y, Wong LY, Meng L, Pittman EN, Trinidad DA, Hubbard KL, Etheredge A, Del Valle-Pinero AY, Zamoiski R, van Bemmel DM, Borek N, Patel V, Kimmel HL, Conway KP, Lawrence C, Edwards KC, Hyland A, Goniewicz ML, Hatsukami D, Hecht SS, Calafat AM.

Environ Int. 2019 Feb;123:201-208. doi: 10.1016/j.envint.2018.11.068. Epub 2018 Dec 6.

5.

Associations of risk factors of e-cigarette and cigarette use and susceptibility to use among baseline PATH study youth participants (2013-2014).

Sawdey MD, Day HR, Coleman B, Gardner LD, Johnson SE, Limpert J, Hammad HT, Goniewicz ML, Abrams DB, Stanton CA, Pearson JL, Kaufman AR, Kimmel HL, Delnevo CD, Compton WM, Bansal-Travers M, Niaura RS, Hyland A, Ambrose BK.

Addict Behav. 2019 Apr;91:51-60. doi: 10.1016/j.addbeh.2018.11.027. Epub 2018 Nov 17.

PMID:
30473246
6.

Transitions in electronic cigarette use among adults in the Population Assessment of Tobacco and Health (PATH) Study, Waves 1 and 2 (2013-2015).

Coleman B, Rostron B, Johnson SE, Persoskie A, Pearson J, Stanton C, Choi K, Anic G, Goniewicz ML, Cummings KM, Kasza KA, Silveira ML, Delnevo C, Niaura R, Abrams DB, Kimmel HL, Borek N, Compton WM, Hyland A.

Tob Control. 2019 Jan;28(1):50-59. doi: 10.1136/tobaccocontrol-2017-054174. Epub 2018 Apr 25.

7.

Body mass index and tobacco-product use among U.S. youth: Findings from wave 1 (2013-2014) of the Population Assessment of Tobacco and Health (PATH) Study.

Green VR, Silveira ML, Kimmel HL, Conway KP.

Addict Behav. 2018 Jun;81:91-95. doi: 10.1016/j.addbeh.2018.02.005. Epub 2018 Feb 5.

8.

US Adult Cigar Smoking Patterns, Purchasing Behaviors, and Reasons for Use According to Cigar Type: Findings From the Population Assessment of Tobacco and Health (PATH) Study, 2013-2014.

Corey CG, Holder-Hayes E, Nguyen AB, Delnevo CD, Rostron BL, Bansal-Travers M, Kimmel HL, Koblitz A, Lambert E, Pearson JL, Sharma E, Tworek C, Hyland AJ, Conway KP, Ambrose BK, Borek N.

Nicotine Tob Res. 2018 Nov 15;20(12):1457-1466. doi: 10.1093/ntr/ntx209.

PMID:
29059423
9.

Co-occurrence of tobacco product use, substance use, and mental health problems among youth: Findings from wave 1 (2013-2014) of the population assessment of tobacco and health (PATH) study.

Conway KP, Green VR, Kasza KA, Silveira ML, Borek N, Kimmel HL, Sargent JD, Stanton CA, Lambert E, Hilmi N, Reissig CJ, Jackson KJ, Tanski SE, Maklan D, Hyland AJ, Compton WM.

Addict Behav. 2018 Jan;76:208-217. doi: 10.1016/j.addbeh.2017.08.009. Epub 2017 Aug 18.

PMID:
28846942
10.

Electronic cigarette use among US adults in the Population Assessment of Tobacco and Health (PATH) Study, 2013-2014.

Coleman BN, Rostron B, Johnson SE, Ambrose BK, Pearson J, Stanton CA, Wang B, Delnevo C, Bansal-Travers M, Kimmel HL, Goniewicz ML, Niaura R, Abrams D, Conway KP, Borek N, Compton WM, Hyland A.

Tob Control. 2017 Dec;26(e2):e117-e126. doi: 10.1136/tobaccocontrol-2016-053462. Epub 2017 Jun 17.

PMID:
28624763
11.

Co-occurrence of tobacco product use, substance use, and mental health problems among adults: Findings from Wave 1 (2013-2014) of the Population Assessment of Tobacco and Health (PATH) Study.

Conway KP, Green VR, Kasza KA, Silveira ML, Borek N, Kimmel HL, Sargent JD, Stanton C, Lambert E, Hilmi N, Reissig CJ, Jackson KJ, Tanski SE, Maklan D, Hyland AJ, Compton WM.

Drug Alcohol Depend. 2017 Aug 1;177:104-111. doi: 10.1016/j.drugalcdep.2017.03.032. Epub 2017 May 30.

12.

Biomarkers of exposure to new and emerging tobacco delivery products.

Schick SF, Blount BC, Jacob P Rd, Saliba NA, Bernert JT, El Hellani A, Jatlow P, Pappas RS, Wang L, Foulds J, Ghosh A, Hecht SS, Gomez JC, Martin JR, Mesaros C, Srivastava S, St Helen G, Tarran R, Lorkiewicz PK, Blair IA, Kimmel HL, Doerschuk CM, Benowitz NL, Bhatnagar A.

Am J Physiol Lung Cell Mol Physiol. 2017 Sep 1;313(3):L425-L452. doi: 10.1152/ajplung.00343.2016. Epub 2017 May 18. Review.

13.

Design and methods of the Population Assessment of Tobacco and Health (PATH) Study.

Hyland A, Ambrose BK, Conway KP, Borek N, Lambert E, Carusi C, Taylor K, Crosse S, Fong GT, Cummings KM, Abrams D, Pierce JP, Sargent J, Messer K, Bansal-Travers M, Niaura R, Vallone D, Hammond D, Hilmi N, Kwan J, Piesse A, Kalton G, Lohr S, Pharris-Ciurej N, Castleman V, Green VR, Tessman G, Kaufman A, Lawrence C, van Bemmel DM, Kimmel HL, Blount B, Yang L, O'Brien B, Tworek C, Alberding D, Hull LC, Cheng YC, Maklan D, Backinger CL, Compton WM.

Tob Control. 2017 Jul;26(4):371-378. doi: 10.1136/tobaccocontrol-2016-052934. Epub 2016 Aug 8.

14.

Effects of pharmacologic dopamine β-hydroxylase inhibition on cocaine-induced reinstatement and dopamine neurochemistry in squirrel monkeys.

Cooper DA, Kimmel HL, Manvich DF, Schmidt KT, Weinshenker D, Howell LL.

J Pharmacol Exp Ther. 2014 Jul;350(1):144-52. doi: 10.1124/jpet.113.212357. Epub 2014 May 9.

15.

Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates.

Felger JC, Mun J, Kimmel HL, Nye JA, Drake DF, Hernandez CR, Freeman AA, Rye DB, Goodman MM, Howell LL, Miller AH.

Neuropsychopharmacology. 2013 Oct;38(11):2179-87. doi: 10.1038/npp.2013.115. Epub 2013 May 9.

16.

The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys.

Manvich DF, Kimmel HL, Cooper DA, Howell LL.

J Pharmacol Exp Ther. 2012 Sep;342(3):761-9. doi: 10.1124/jpet.112.195156. Epub 2012 Jun 8.

17.

Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use.

Sawyer EK, Mun J, Nye JA, Kimmel HL, Voll RJ, Stehouwer JS, Rice KC, Goodman MM, Howell LL.

Neuropsychopharmacology. 2012 Jul;37(8):1816-24. doi: 10.1038/npp.2012.29. Epub 2012 Mar 21.

18.

Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys.

Manvich DF, Kimmel HL, Howell LL.

J Pharmacol Exp Ther. 2012 May;341(2):424-34. doi: 10.1124/jpet.111.186981. Epub 2012 Feb 10.

19.

The cystine-glutamate transporter enhancer N-acetyl-L-cysteine attenuates cocaine-induced changes in striatal dopamine but not self-administration in squirrel monkeys.

Bauzo RM, Kimmel HL, Howell LL.

Pharmacol Biochem Behav. 2012 Apr;101(2):288-96. doi: 10.1016/j.pbb.2011.12.018. Epub 2011 Dec 31.

20.

Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys.

Kimmel HL, Nye JA, Voll R, Mun J, Stehouwer J, Goodman MM, Votaw JR, Carroll FI, Howell LL.

Synapse. 2012 Jun;66(6):501-8. doi: 10.1002/syn.21536. Epub 2012 Mar 16.

21.

The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study.

Murnane KS, Kimmel HL, Rice KC, Howell LL.

Horm Behav. 2012 Feb;61(2):181-90. doi: 10.1016/j.yhbeh.2011.10.012. Epub 2011 Dec 14.

22.

Behavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkey.

Kimmel HL, Manvich DF, Blough BE, Negus SS, Howell LL.

Pharmacol Biochem Behav. 2009 Dec;94(2):278-84. doi: 10.1016/j.pbb.2009.09.007. Epub 2009 Sep 17.

23.

Interactions between the mGluR2/3 agonist, LY379268, and cocaine on in vivo neurochemistry and behavior in squirrel monkeys.

Bauzo RM, Kimmel HL, Howell LL.

Pharmacol Biochem Behav. 2009 Nov;94(1):204-10. doi: 10.1016/j.pbb.2009.08.011. Epub 2009 Aug 22.

24.

Effects of the monoamine uptake inhibitors RTI-112 and RTI-113 on cocaine- and food-maintained responding in rhesus monkeys.

Negus SS, Mello NK, Kimmel HL, Howell LL, Carroll FI.

Pharmacol Biochem Behav. 2009 Jan;91(3):333-8. doi: 10.1016/j.pbb.2008.08.002. Epub 2008 Aug 8.

25.

Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys.

Kimmel HL, Negus SS, Wilcox KM, Ewing SB, Stehouwer J, Goodman MM, Votaw JR, Mello NK, Carroll FI, Howell LL.

Pharmacol Biochem Behav. 2008 Sep;90(3):453-62. doi: 10.1016/j.pbb.2008.03.032. Epub 2008 Apr 4.

26.

Monoamine transporters and psychostimulant addiction.

Howell LL, Kimmel HL.

Biochem Pharmacol. 2008 Jan 1;75(1):196-217. Epub 2007 Aug 7. Review.

PMID:
17825265
27.

Intra-VTA CART 55-102 reduces the locomotor effect of systemic cocaine in rats: an isobolographic analysis.

Jaworski JN, Kimmel HL, Mitrano DA, Tallarida RJ, Kuhar MJ.

Neuropeptides. 2007 Apr;41(2):65-72. Epub 2007 Feb 7.

28.

Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys.

Kimmel HL, O'Connor JA, Carroll FI, Howell LL.

Pharmacol Biochem Behav. 2007 Jan;86(1):45-54. Epub 2006 Dec 20.

29.

Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys.

Howell LL, Carroll FI, Votaw JR, Goodman MM, Kimmel HL.

J Pharmacol Exp Ther. 2007 Feb;320(2):757-65. Epub 2006 Nov 14.

PMID:
17105829
30.

In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys.

Wilcox KM, Kimmel HL, Lindsey KP, Votaw JR, Goodman MM, Howell LL.

Synapse. 2005 Dec 15;58(4):220-8.

PMID:
16206183
31.

Olanzapine-induced suppression of cocaine self-administration in rhesus monkeys.

Howell LL, Wilcox KM, Lindsey KP, Kimmel HL.

Neuropsychopharmacology. 2006 Mar;31(3):585-93.

32.

Changes in extracellular dopamine during cocaine self-administration in squirrel monkeys.

Kimmel HL, Ginsburg BC, Howell LL.

Synapse. 2005 Jun 1;56(3):129-34.

PMID:
15765537
33.

Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys.

Ginsburg BC, Kimmel HL, Carroll FI, Goodman MM, Howell LL.

Pharmacol Biochem Behav. 2005 Mar;80(3):481-91.

PMID:
15740791
34.

CART peptides are modulators of mesolimbic dopamine and psychostimulants.

Jaworski JN, Vicentic A, Hunter RG, Kimmel HL, Kuhar MJ.

Life Sci. 2003 Jun 27;73(6):741-7. Review.

PMID:
12801595
35.

Withdrawal from repeated cocaine alters dopamine transporter protein turnover in the rat striatum.

Kimmel HL, Carroll FI, Kuhar MJ.

J Pharmacol Exp Ther. 2003 Jan;304(1):15-21.

PMID:
12490570
36.

Activity of various CART peptides in changing locomotor activity in the rat.

Kimmel HL, Thim L, Kuhar MJ.

Neuropeptides. 2002 Feb;36(1):9-12.

PMID:
12147209
37.

Locomotor stimulant effects of novel phenyltropanes in the mouse.

Kimmel HL, Carroll FI, Kuhar MJ.

Drug Alcohol Depend. 2001 Dec 1;65(1):25-36.

PMID:
11714587
38.

Dopamine D1 and D2 receptors influence dopamine transporter synthesis and degradation in the rat.

Kimmel HL, Joyce AR, Carroll FI, Kuhar MJ.

J Pharmacol Exp Ther. 2001 Jul;298(1):129-40.

PMID:
11408534
39.
40.
41.
42.

Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using RTI-76.

Kimmel HL, Carroll FI, Kuhar MJ.

Neuropharmacology. 2000 Feb 14;39(4):578-85.

PMID:
10728879
43.

Sensitization to daily morphine injections in rats with unilateral lesions of the substantia nigra.

Volpicelli LA, Easterling KW, Kimmel HL, Holtzman SG.

Pharmacol Biochem Behav. 1999 Nov;64(3):487-93.

PMID:
10548260
44.
45.

Naloxone does not alter amphetamine-induced rotational behavior or striatal dopamine levels of nigrally-lesioned rats.

Kimmel HL, Schad CA, Justice JB Jr, Holtzman SG.

Brain Res. 1998 Apr 6;789(1):171-4.

PMID:
9602114
46.

Opioid receptor agonists and antagonists alter GBR12909-induced turning in the rat.

Kimmel HL, Holtzman SG.

Eur J Pharmacol. 1998 Feb 19;343(2-3):119-27.

PMID:
9570458
47.

Theory and statistics of detecting synergism between two active drugs: cocaine and buprenorphine.

Tallarida RJ, Kimmel HL, Holtzman SG.

Psychopharmacology (Berl). 1997 Oct;133(4):378-82.

PMID:
9372538
48.

Synergism between buprenorphine and cocaine on the rotational behavior of the nigrally-lesioned rat.

Kimmel HL, Tallarida RJ, Holtzman SG.

Psychopharmacology (Berl). 1997 Oct;133(4):372-7.

PMID:
9372537
49.

Mu opioid agonists potentiate amphetamine- and cocaine-induced rotational behavior in the rat.

Kimmel HL, Holtzman SG.

J Pharmacol Exp Ther. 1997 Aug;282(2):734-46.

PMID:
9262337
50.

Effects of acute and chronic morphine on rotational behavior in nigral-lesioned rats.

Kimmel HL, Garrett BE, Holtzman SG.

Pharmacol Biochem Behav. 1995 Oct;52(2):397-401.

PMID:
8577807

Supplemental Content

Loading ...
Support Center